To develop a site-specifically radiolabeled version of IMMU-132 (sacituzumab govitecan) using zirconium-89 (⁸⁹Zr) with the chelator 3,4,3-LI(1,2-HOPO) and evaluate its stability, specificity, and quantitative targeting ability in TROP-2–positive prostate cancer models.

IMMU-132 was conjugated to 3,4,3-LI(1,2-HOPO)-maleimide and its integrity was confirmed by SDS-PAGE, SE-HPLC and mass spectrometry. Radiolabeling with ⁸⁹Zr was performed, and radiochemical yield and purity were measured. In vitro s...

This study aimed to determine the optimized scan time and injected activity regimen for clinical⁶⁸Ga DOTATATE PET/CT in neuroendocrine tumor imaging through an experimental approach without using machine learning techniques.

A NEMA PET body phantom was used with Ga-⁶⁸to simulate a 9:1 sphere-to-background ratio. PET data were acquired on a high-sensitivity scanner at various scan times (15–300 s/bed). For each scan time, coefficient of variation (COV) and contrast-to-noise ratio (CNR) were calcul...

Intermittent hydrarthrosis, also referred to as periodic synoviosis, or periodic hydrarthritis, is a rare autoinflammatory condition that manifests as periodic, unprovoked, and transient arthritis affecting usually the knee joint1. It is characterized by recurring episodes of temporary fluid accumulation. Finding an effective treatment is challenging. NSAIDs and intra-articular steroids are usually not useful. Currently, there is no established standard treatment for this condition. However, the...

Noonan syndrome (NS) is a pleiotropic autosomal dominant RAS/MAPK pathway disorder affecting 1 in 1000–2500 live births123. Cardinal features include a characteristic facial appearance, short stature, congenital heart disease, and developmental delay12. Pathogenic variants in genes such asPTPN11,SOS1, andKRAScause RAS/MAPK pathway dysregulation, classifying NS as a “RASopathy”45. Lymphatic abnormalities, including peripheral oedema, protein-losing enteropathy, or chylothorax, affect approximatel...

With personalized tumor therapy, understanding and addressing the heterogeneity of malignant tumors is becoming increasingly important. Heterogeneity can be found within one lesion (intralesional) and between several tumor lesions emerging from one primary tumor (interlesional). The heterogeneous tumor cells may show a different response to treatment due to their biology, which in turn influences the outcome of the affected patients and the choice of therapeutic agents. Therefore, both intra- an...